CTIS2024-511292-15-00进行中（未招募）1 期
Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. - GETNE-T2216
Grupo Espanol De Tumores Neuroendocrinos0 个研究点目标入组 41 人开始时间: 2024年2月29日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 41
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Male or female subjects = 18 years old., Female subjects of childbearing potential (WOCBP) must provide a negative urine pregnancy test at screening, and must agree to use a medically accepted and highly effective birth control method (i.e. those with a failure rate less than 1%; refer to Appendix 5) for the duration of the study treatment and for 4 months after the final dose of cabozantinib. ? A woman is considered of childbearing potential ( i.e. fertile) following menarche and until becoming post-menopausal unless permanently sterile. Women will be considered post-menopausal if they have been amenorrhoeic for 12 months without an alternative medical cause. The following age-specific requirements apply: a. Amenorrheic for =1 year in the absence of chemotherapy and/or hormonal treatments b. Luteinizing hormone (LH) and/or follicle stimulating hormone and/or estradiol levels in the post-menopausal range c. Radiation induced oophorectomy with last menses >1 year ago d. Chemotherapy induced menopause with >1 year interval since last menses e. Surgical sterilization (bilateral oophorectomy or hysterectomy) f. Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy) g. Women =50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy)., Non-sterile males must be willing to use a highly effective method of birth control for the duration of the study treatment and for 4 months after the final dose of cabozantinib. ? A sterile male is defined as: a. One for whom azoospermia has been previously demonstrated in a semen sample examination as definitive evidence of infertility. b. Males with known low sperm counts” (consistent with sub-fertility”) are not to be considered sterile for purposes of this study., Capable of understanding and complying with the protocol requirements and signed informed consent., Written informed consent approved by the Independent Ethics Committee (IEC), prior to the performance of any trial activities., Histologically or cytologically confirmed diagnosis of DTC, including the following subtypes: (Note: results of a previous biopsy will be accepted): a. Papillary thyroid carcinoma (PTC) including histological variants of PTC such as follicular variant, tall cell, columnar cell, cribriform-morular, solid, oxyphil, Warthin-like, trabecular, tumor with nodular fasciitis-like stroma, Hürthle cell variant of papillary carcinoma, poorly differentiated. b. Follicular thyroid carcinoma (FTC) including histological variants of FTC such as Hürthle cell, clear cell, insular, and poorly differentiated., Measurable disease according to RECIST 1.1 (Appendix 3) on computed tomography/magnetic resonance imaging (CT/MRI) performed within 28 days prior to first dose of study treatment., Must have been previously treated with or deemed ineligible for treatment with Iodine-131 for DTC., Must have been previously treated and experienced documented radiographic progression per RECIST 1.1 with one or two of the following VEGF-targeting
排除标准
- •Prior treatment with any of the following: a. Cabozantinib. b. Selective small-molecule BRAF kinase inhibitor (eg, vemurafenib, dabrafenib). c. Immune checkpoint inhibitor therapy (eg, PD-1 or PD-L1 targeting agent). d. Systemic chemotherapy regimen (given as a single agent or in combination with another chemotherapy agent), Patients who are not able to swallow tablets., Previously identified allergy or hypersensitivity to components of the study treatment formulations., Diagnosis of another malignancy within 3 years before the first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy., Women pregnant or breastfeeding. Fertile and sexually active patients who are not willing to use the appropriate highly effective contraceptive methods., Any underlying medical or psychiatric disorder, which, in the opinion of the investigator, makes the administration of cabozantinib unsafe or interferes with the informed consent process or trial procedures., Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks or 5 half-lives of the agent, whichever is longer, before first dose of study treatment., Receipt of any type of anticancer antibody (including investigational antibody) within 4 weeks before first dose of study treatment., Receipt of radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before first dose of study treatment. Patients with clinically relevant ongoing complications from prior radiation therapy that have not completely resolved are not eligible (eg, radiation esophagitis or other inflammation of the viscera)., Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of inclusion., Concomitant anticoagulation with oral anticoagulants (eg, warfarin, direct thrombin and Factor Xa inhibitors) or platelet inhibitors (eg, clopidogrel), except for the following allowed anticoagulants: a. Low-dose aspirin for cardioprotection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH). b. Anticoagulation with therapeutic doses of LMWH in subjects without known brain metastases who are on a stable dose of LMWH for at least 6 weeks before first dose of study treatment and who have had no clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor., The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions: a. Cardiovascular disorders: i. ii. iii. Congestive heart failure class 3 or 4 as defined by the New York Heart Association, unstable angina pectoris, serious cardiac arrhythmias. Uncontrolled hypertension defined as sustained BP > 150 mm Hg systolic or > 100 mm Hg diastolic despite optimal antihypertensive treatment. Stroke (including transient ischemic attack [TIA]), myocardial infarction, or other ischemic event, or thromboembolic event (eg, deep venous thrombosis [DVT], pulmonary embolism) within 6 months before first dose of study treatment. Note: Patients with a more recent diagnosis of DVT are allowed if stable, asymptomatic, and treated with LMWH for at least 6 we
研究者
相似试验
已完成
1 期
METBEIGE Studycolorectal cancerJPRN-jRCT2080224606ational Cancer Center Hospital East54
进行中（未招募）
1 期
Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulatioStage III B or stage IV non-small cell lung cancer (not a candidate for local therapies with curative intent)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004157-16-ITFONDAZIONE RICERCA TRASLAZIONALE (FORT)25
已完成
2 期
Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.Differentiated Thyroid CancerNCT05660954Grupo Espanol de Tumores Neuroendocrinos41
已完成
不适用
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid TumorsNL-OMON50370Exelixis, Inc25
招募中
1 期
A phase II trial of Cabozantinib medication in patients with advanced, high-grade neuroendocrine neoplasms, which are either well-differentiated neuroendocrine tumors or poor-differentiated neuroendocrine carcinoma but with a low proliferation rate. Both neuroendocrine neoplasms are insensitive against the available chemotherapy choice, making the newly investigated medication a new hope for better management of these subtypes.We will include patients with NET G3 in upto four different antitumoral therapies and NEC Ki67 low after failure of standard treatment with conventional chemotherapy.EUCTR2020-002541-41-ATniversitätsmedizin Göttingen